Compare CRC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | CRSP |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.8B |
| IPO Year | 2020 | 2016 |
| Metric | CRC | CRSP |
|---|---|---|
| Price | $53.96 | $51.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 23 |
| Target Price | $75.33 | ★ $85.63 |
| AVG Volume (30 Days) | 724.3K | ★ 1.4M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $3,669,000,000.00 | $289,590,000.00 |
| Revenue This Year | $5.44 | $1,052.09 |
| Revenue Next Year | N/A | $280.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.73 | ★ 9169.85 |
| 52 Week Low | $43.25 | $44.12 |
| 52 Week High | $71.98 | $65.98 |
| Indicator | CRC | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 47.75 |
| Support Level | $50.16 | $50.19 |
| Resistance Level | $55.12 | $60.71 |
| Average True Range (ATR) | 1.66 | 2.15 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 77.40 | 58.72 |
California Resources Corp is an independent oil and natural gas exploration and production company. The company has operations spread across different properties in several oil and gas exploration basins in California and Utah, such as the Midway-Sunset, South Belridge, and McKittrick fields, in the San Joaquin Basin, and other properties located in Los Angeles, Sacramento, Uinta, and the Ventura and Salinas basins. Additionally, the company is focused on maximizing the value of its land, mineral ownership, and energy expertise for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects. Its business is organized into two reporting segments: oil and natural gas, which generate maximum revenue, and carbon management.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.